Head Katharine J, Hayes Lisa R, Miller Nadia E, Shakil Safia, Bales Casey L, Schneider Bryan P
Department of Communication Studies, 425 University Blvd, Indiana University-Purdue University Indianapolis, IN, 46202, United States.
Pink-4-Ever Ending Disparities, 8770 Commerce Park Place F, Indianapolis, IN 46286, United States.
PEC Innov. 2022 Dec 13;2:100118. doi: 10.1016/j.pecinn.2022.100118. eCollection 2023 Dec.
Many Black breast cancer patients experience chemotherapy-induced peripheral neuropathy (CIPN). Our study assessed Black breast cancer patients' questions about a biomarker test that can predict likelihood of CIPN.
Nineteen Black women who were previous/current breast cancer patients participated in focus groups. Researchers briefly explained CIPN and the biomarker test, and then participants were asked what questions they would have about the test and its use in treatment decisions. These participant-voiced questions composed the data for this study and were analyzed using thematic analysis.
Participants' questions centered on six themes: reasons for the test, effect on timeline of breast cancer treatment, testing procedure, limits of test (including accuracy), research done to develop this test (including research participants), and concerns about personal information connected to the test (including DNA).
This study provides an exploratory look at questions that Black breast cancer patients may have about toxicity biomarker testing use in breast cancer treatment decisions.
These findings provide a starting point for developing patient-centered approaches for integrating this precision medicine tool into clinical care. The methodological choice to generate participants' questions (rather than answers to a question) led to robust, actionable data.
许多黑人乳腺癌患者会经历化疗引起的周围神经病变（CIPN）。我们的研究评估了黑人乳腺癌患者对于一种能够预测CIPN可能性的生物标志物检测的疑问。
19名曾患/现患乳腺癌的黑人女性参与了焦点小组。研究人员简要解释了CIPN和生物标志物检测，然后询问参与者对于该检测及其在治疗决策中的应用有哪些疑问。这些参与者提出的问题构成了本研究的数据，并采用主题分析法进行分析。
参与者的问题集中在六个主题上：检测的原因、对乳腺癌治疗时间线的影响、检测程序、检测的局限性（包括准确性）、开发此检测所做的研究（包括研究参与者）以及对与检测相关的个人信息（包括DNA）的担忧。
本研究对黑人乳腺癌患者在乳腺癌治疗决策中可能对毒性生物标志物检测使用存在的疑问进行了探索性研究。
这些发现为开发以患者为中心的方法将这种精准医学工具整合到临床护理中提供了一个起点。生成参与者问题（而非问题答案）的方法选择产生了有力且可付诸行动的数据。
